These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34245199)

  • 1. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 2. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy.
    Schön M; Domingues S; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2023 May; 44(5):1803-1804. PubMed ID: 36645532
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
    Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
    Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
    Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
    Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
    Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
    Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
    Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
    Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
    [No Abstract]   [Full Text] [Related]  

  • 10. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
    Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
    Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
    Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
    J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
    Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
    Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating adults with spinal muscular atrophy with nusinersen.
    Farrar MA; Kiernan MC
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
    [No Abstract]   [Full Text] [Related]  

  • 14. Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen.
    Ogawa K; Okanari K; Kobayashi O; Nakashima M; Ihara K
    Pediatr Int; 2019 Oct; 61(10):1051-1053. PubMed ID: 31612561
    [No Abstract]   [Full Text] [Related]  

  • 15. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
    Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
    Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
    de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
    J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
    LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
    Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
    [No Abstract]   [Full Text] [Related]  

  • 19. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
    Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
    Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.